FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128374908> ?p ?o ?g. }

• W2128374908 endingPage "16782" @default.
• W2128374908 startingPage "16776" @default.
• W2128374908 abstract "Inflammation is a homeostatic mechanism that limits the effects of infectious agents. Tumor necrosis factor (TNF) and interleukin (IL)-1 are two cytokines that induce inflammation through activation of the transcription factor NF-κB. Various studies have suggested that two homologous and structurally related adapter proteins TAB2 and TAB3 play redundant roles in TNF- and IL-1-mediated NF-κB activation pathways. Both TAB2 and TAB3 contain CUE, coiled-coil, and nuclear protein localization 4 zinc finger (NZF) domains. The NZF domains of TAB2/3 are critical for TAB2/3 to bind to Lys63-linked polyubiquitin chains of other adaptor proteins, such as receptor-interacting protein and TRAF6, which are two signaling proteins essential for TNF- and IL-1-induced NF-κB activation, respectively. In a search for proteins containing NZF domains conserved with those of TAB2/3, we identified RBCK1, which has been shown to act as an E3 ubiquitin ligase in iron metabolism. Overexpression of RBCK1 negatively regulates TAB2/3-mediated and TNF- and IL-1-induced NF-κB activation, whereas knockdown of RBCK1 by RNA interference potentiates TNF- and IL-1-induced NF-κB activation. RBCK1 physically interacts with TAB2/3 and facilitates degradation of TAB2/3 through a proteasome-dependent process. Taken together, our findings suggest that RBCK1 is involved in negative regulation of inflammatory signaling triggered by TNF and IL-1 through targeting TAB2/3 for degradation. Inflammation is a homeostatic mechanism that limits the effects of infectious agents. Tumor necrosis factor (TNF) and interleukin (IL)-1 are two cytokines that induce inflammation through activation of the transcription factor NF-κB. Various studies have suggested that two homologous and structurally related adapter proteins TAB2 and TAB3 play redundant roles in TNF- and IL-1-mediated NF-κB activation pathways. Both TAB2 and TAB3 contain CUE, coiled-coil, and nuclear protein localization 4 zinc finger (NZF) domains. The NZF domains of TAB2/3 are critical for TAB2/3 to bind to Lys63-linked polyubiquitin chains of other adaptor proteins, such as receptor-interacting protein and TRAF6, which are two signaling proteins essential for TNF- and IL-1-induced NF-κB activation, respectively. In a search for proteins containing NZF domains conserved with those of TAB2/3, we identified RBCK1, which has been shown to act as an E3 ubiquitin ligase in iron metabolism. Overexpression of RBCK1 negatively regulates TAB2/3-mediated and TNF- and IL-1-induced NF-κB activation, whereas knockdown of RBCK1 by RNA interference potentiates TNF- and IL-1-induced NF-κB activation. RBCK1 physically interacts with TAB2/3 and facilitates degradation of TAB2/3 through a proteasome-dependent process. Taken together, our findings suggest that RBCK1 is involved in negative regulation of inflammatory signaling triggered by TNF and IL-1 through targeting TAB2/3 for degradation. Proinflammatory cytokines, such as TNF 3The abbreviations used are: TNF, tumor necrosis factor; IL, interleukin; NF-κB, nuclear factor κB; CC, coiled-coil; NZF, HA, hemagglutinin; E3, ubiquitin-protein isopeptide ligase; CREB, cAMP-response element-binding protein; aa, amino acids; RNAi, RNA interference; IFN, interferon. and IL-1, play critical roles in inflammatory processes and are involved in regulation of immune responses. Stimulation of cells with TNF or IL-1β initiates a cascade of signaling events leading to activation of transcription factors NF-κB and AP1 (activator protein 1) and induction of proinflammatory cytokines (1Aggarwal B.B. Nat. Rev. Immunol. 2003; 3: 745-756Crossref PubMed Scopus (2164) Google Scholar, 2Dunne A. O'Neill L.A. Sci. STKE 2003. 2003; : re3Google Scholar). NF-κB regulates expression of a large number of genes involved in immune responses, inflammation, cell survival, and cancer (3Ghosh S. Karin M. Cell. 2002; 109: 81-96Abstract Full Text Full Text PDF PubMed Scopus (3294) Google Scholar). NF-κB is sequestered in the cytoplasm and kept inactive in nonstimulated cells through binding to inhibitory IκB (inhibitor of κB) proteins. Following stimulation with cytokines, infectious agents, or radiation-induced DNA double-stranded breaks, the IκB proteins are phosphorylated, ubiquitinated, and ultimately degraded in a proteasome-dependent manner, which frees NF-κB from IκB proteins to translocate to the nucleus, where it activates transcription of target genes (3Ghosh S. Karin M. Cell. 2002; 109: 81-96Abstract Full Text Full Text PDF PubMed Scopus (3294) Google Scholar). Considerable progress has been made during the past couple of decades in identifying molecular components involved in TNF- and IL-1-triggered NF-κB activation pathways. Binding of TNF to TNFR-I leads to its trimerization and the recruitment of adaptor proteins, including TRADD, TRAF2, and receptor-interacting protein (RIP) (1Aggarwal B.B. Nat. Rev. Immunol. 2003; 3: 745-756Crossref PubMed Scopus (2164) Google Scholar). RIP is subsequently polyubiquitinated in a Lys48- or Lys63-linked manner, among which Lys63-linked ubiquitination of RIP is required for the recruitment and activation of TAK1 (TGF-β-activated kinase 1), a kinase associated with adapter proteins TAB2 (TAK1-binding protein 2) and TAB3 (TAK1-binding protein 3) (4Kanayama A. Seth R.B. Sun L. Ea C.K. Hong M. Shaito A. Chiu Y.H. Deng L. Chen Z.J. Mol. Cell. 2004; 15: 535-548Abstract Full Text Full Text PDF PubMed Scopus (700) Google Scholar, 5Wertz I.E. O'Rourke K.M. Zhou H. Eby M. Aravind L. Seshagiri S. Wu P. Wiesmann C. Baker R. Boone D.L. Ma A. Koonin E.V. Dixit V.M. Nature. 2004; 430: 694-699Crossref PubMed Scopus (1470) Google Scholar). The activated TAK1 subsequently activates downstream kinases IKKα and IKKβ, which phosphorylate IκB proteins, and leads to NF-κB activation (6Hacker H. Karin M. Sci. STKE 2006. 2006; : re13Google Scholar). Upon IL-1 stimulation, the IL-1-receptor recruits IL-1-receptor accessory protein to form an activated receptor complex (7Wesche H. Korherr C. Kracht M. Falk W. Resch K. Martin M.U. J. Biol. Chem. 1997; 272: 7727-7731Abstract Full Text Full Text PDF PubMed Scopus (267) Google Scholar, 8Greenfeder S.A. Nunes P. Kwee L. Labow M. Chizzonite R.A. Ju G. J. Biol. Chem. 1995; 270: 13757-13765Abstract Full Text Full Text PDF PubMed Scopus (560) Google Scholar, 9Huang J. Gao X. Li S. Cao Z. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 12829-12832Crossref PubMed Scopus (195) Google Scholar), which further recruits adaptor proteins, including MyD88, IRAK4, and IRAK1 (10Burns K. Martinon F. Esslinger C. Pahl H. Schneider P. Bodmer J.L. Di Marco F. French L. Tschopp J. J. Biol. Chem. 1998; 273: 12203-12209Abstract Full Text Full Text PDF PubMed Scopus (520) Google Scholar, 11Cao Z. Henzel W.J. Gao X. Science. 1996; 271: 1128-1131Crossref PubMed Scopus (773) Google Scholar, 12Wesche H. Henzel W.J. Shillinglaw W. Li S. Cao Z. Immunity. 1997; 7: 837-847Abstract Full Text Full Text PDF PubMed Scopus (920) Google Scholar). Phosphorylation of IRAK1 by IRAK4 results in recruitment and binding of TRAF6 (TNF receptor-associated factor 6) to the complex, which is followed by the release of IRAK1-TRAF6 from the receptor complex to form another complex with TAK1-TAB1-TAB2 or TAK1-TAB1-TAB3 that are preassociated on the membrane (13Cao Z. Xiong J. Takeuchi M. Kurama T. Goeddel D.V. Nature. 1996; 383: 443-446Crossref PubMed Scopus (1122) Google Scholar, 14Lomaga M.A. Yeh W.C. Sarosi I. Duncan G.S. Furlonger C. Ho A. Morony S. Capparelli C. Van G. Kaufman S. van der Heiden A. Itie A. Wakeham A. Khoo W. Sasaki T. Cao Z. Penninger J.M. Paige C.J. Lacey D.L. Dunstan C.R. Boyle W.J. Goeddel D.V. Mak T.W. Genes Dev. 1999; 13: 1015-1024Crossref PubMed Scopus (1083) Google Scholar, 15Li S. Strelow A. Fontana E.J. Wesche H. Proc. Natl. Acad. Sci. U. S. A. 2002; 99: 5567-5572Crossref PubMed Scopus (543) Google Scholar, 16Suzuki N. Suzuki S. Duncan G.S. Millar D.G. Wada T. Mirtsos C. Takada H. Wakeham A. Itie A. Li S. Penninger J.M. Wesche H. Ohashi P.S. Mak T.W. Yeh W.C. Nature. 2002; 416: 750-756Crossref PubMed Scopus (666) Google Scholar, 17Jiang Z. Ninomiya-Tsuji J. Qian Y. Matsumoto K. Li X. Mol. Cell. Biol. 2002; 22: 7158-7167Crossref PubMed Scopus (238) Google Scholar, 18Cheung P.C. Nebreda A.R. Cohen P. Biochem. J. 2004; 378: 27-34Crossref PubMed Scopus (135) Google Scholar). In this latter complex, TRAF6 is autopolyubiquitinated with Lys63-linked ubiquitin chains, through which it interacts with adaptor proteins TAB2 and TAB3, leading to the binding and activation of TAK1 and subsequently the activation of IKK and NF-κB (4Kanayama A. Seth R.B. Sun L. Ea C.K. Hong M. Shaito A. Chiu Y.H. Deng L. Chen Z.J. Mol. Cell. 2004; 15: 535-548Abstract Full Text Full Text PDF PubMed Scopus (700) Google Scholar, 19Takaesu G. Kishida S. Hiyama A. Yamaguchi K. Shibuya H. Irie K. Ninomiya-Tsuji J. Matsumoto K. Mol. Cell. 2000; 5: 649-658Abstract Full Text Full Text PDF PubMed Scopus (491) Google Scholar, 20Deng L. Wang C. Spencer E. Yang L. Braun A. You J. Slaughter C. Pickart C. Chen Z.J. Cell. 2000; 103: 351-361Abstract Full Text Full Text PDF PubMed Scopus (1513) Google Scholar, 21Wang C. Deng L. Hong M. Akkaraju G.R. Inoue J. Chen Z.J. Nature. 2001; 412: 346-351Crossref PubMed Scopus (1639) Google Scholar). As described above, the adaptor proteins TAB2 and TAB3 are critical intermediates for both TNF- and IL-1-induced activation of NF-κB. TAB2 deficiency was embryonic lethal due to liver degeneration and apoptosis. However, TAB2-deficient cells were still capable of activating IKK and JNK in response to TNF, IL-1, and lipopolysaccharide (22Sanjo H. Takeda K. Tsujimura T. Ninomiya-Tsuji J. Matsumoto K. Akira S. Mol. Cell. Biol. 2003; 23: 1231-1238Crossref PubMed Scopus (105) Google Scholar), whereas knockdown of both TAB2 and TAB3 inhibits IKK and JNK activation induced by TNF and IL-1, suggesting that TAB2 and TAB3 play redundant roles in TNF- and IL-1-triggered signaling (23Ishitani T. Takaesu G. Ninomiya-Tsuji J. Shibuya H. Gaynor R.B. Matsumoto K. EMBO J. 2003; 22: 6277-6288Crossref PubMed Scopus (219) Google Scholar). TAB2 and TAB3 are structurally related, and both contain an N-terminal CUE domain and C-terminal coiled-coil (CC) and nuclear protein localization 4 (Npl4) zinc finger (NZF) domains (24Wang B. Alam S.L. Meyer H.H. Payne M. Stemmler T.L. Davis D.R. Sundquist W.I. J. Biol. Chem. 2003; 278: 20225-20234Abstract Full Text Full Text PDF PubMed Scopus (122) Google Scholar). TAB2 and TAB3 physically link TAK1 to RIP upon TNF stimulation and to TRAF6 upon IL-1β stimulation mainly through their respective NZF domains (4Kanayama A. Seth R.B. Sun L. Ea C.K. Hong M. Shaito A. Chiu Y.H. Deng L. Chen Z.J. Mol. Cell. 2004; 15: 535-548Abstract Full Text Full Text PDF PubMed Scopus (700) Google Scholar). Collectively, TNF stimulation leads to a RIP-TAB2/3-TAK1 complex, whereas IL-1 stimulation leads to the formation of a TRAF6-TAB2/3-TAK1 complex, both of which are critical for the signaling pathways leading to NF-κB activation. In this study, we found that the NZF-containing protein RBCK1 (RBCC protein interacting with protein kinase C1) interacts with TAB2 and TAB3 and targets them for degradation in a proteasome-dependent manner. Overexpression of RBCK1 inhibits TAB2/3-mediated and TNF- and IL-1-induced NF-κB activation, whereas knockdown of RBCK1 by RNAi potentiates TNF- and IL-1-induced NF-κB activation. Our findings suggest that RBCK1 plays an inhibitory role in inflammatory signaling pathways. Reagents and Antibodies—Recombinant TNF, IL-1β, and IFN-γ were purchased from R&D Systems. Mouse monoclonal antibodies against FLAG (M2) and HA epitopes and MGC132 (Sigma), rabbit polyclonal antibodies against ubiquitin and glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz Biotechnology), were purchased from the indicated manufacturers. Mouse anti-RBCK1, mouse anti-TAB2, and rabbit anti-TAK1 were raised against recombinant human full-length RBCK1, TAB2, and TAK1 proteins, respectively. Constructs—Mammalian expression plasmids for human HA- or FLAG-tagged RBCK1, TAB1, TAK1, TAB2, and TAB3 and their mutants were constructed by standard molecular biology techniques. Mammalian expression plasmids for HA-RIP, HA-TAK1, HA-TRAF2, and HA-TRAF6 were described previously (25Chen D. Li X. Zhai Z. Shu H.B. J. Biol. Chem. 2002; 277: 15985-15991Abstract Full Text Full Text PDF PubMed Scopus (55) Google Scholar, 26Xu L.G. Wang Y.Y. Han K.J. Li L.Y. Zhai Z. Shu H.B. Mol. Cell. 2005; 19: 727-740Abstract Full Text Full Text PDF PubMed Scopus (1508) Google Scholar). NF-κB luciferase reporter plasmid was provided by Dr. Gary Johnson. Transfection and Reporter Gene Assays—293 cells (∼5 × 104) were seeded on 24-well dishes and transfected the following day by standard calcium phosphate precipitation. Where necessary, empty control plasmid was added to ensure that each transfection receives the same amount of total DNA. To normalize for transfection efficiency, 0.1 μg of pRL-TK Renilla luciferase reporter plasmid was added to each transfection. Approximately 20 h after transfection, luciferase assays were performed using a dual specific luciferase assay kit (Promega, Madison, WI). Firefly luciferase activities were normalized based on Renilla luciferase activities. All reporter gene assays were repeated at least three times. Data shown were average values ± S.D. from one representative experiment. Co-immunoprecipitation and Western Blot Analysis—Transient transfection and co-immunoprecipitation, as well as endogenous coimmunoprecipitation experiments, were performed as described (27Shu H.B. Takeuchi M. Goeddel D.V. Proc. Natl. Acad. Sci. U. S. A. 1996; 93: 13973-13978Crossref PubMed Scopus (366) Google Scholar). RNAi Experiments—Double-stranded oligonucleotides corresponding to the target sequences were cloned into the pSuper. Retro RNAi plasmid (Oligoengine Inc.). The following sequences were targeted for human RBCK1 cDNA: oligonucleotide 1, 5′-GACCCCAGATTGCAAGGGA-3′; oligonucleotide 2, 5′-TGAGTTCACCTGCCCTGTG-3′; oligonucleotide 3, 5′-GGCCATCCATGAGCAGATG-3′; oligonucleotide 4, 5′-CTGCAAGGAGTATCAGGAG-3′; oligonucleotide 5, 5′-GGAGTATCAGGAGGACCTG-3′. RBCK1 Interacts with TAB2 and TAB3—Previous studies have indicated that the CC domains of TAB2/3 are required for their ubiquitination and protein-protein interaction (23Ishitani T. Takaesu G. Ninomiya-Tsuji J. Shibuya H. Gaynor R.B. Matsumoto K. EMBO J. 2003; 22: 6277-6288Crossref PubMed Scopus (219) Google Scholar), whereas the NZF domains are critically involved in binding to polyubiquitin chains of RIP and TRAF6, which is key to TNF- and IL-1-induced NF-κB activation (4Kanayama A. Seth R.B. Sun L. Ea C.K. Hong M. Shaito A. Chiu Y.H. Deng L. Chen Z.J. Mol. Cell. 2004; 15: 535-548Abstract Full Text Full Text PDF PubMed Scopus (700) Google Scholar). To further understand the roles of TAB2/3 in TNF- and IL-1-triggered NF-κB activation pathways, we sought to identify proteins containing NZF domains similar to those of TAB2/3. Data base searches led to identification of RBCK1, also called HOIL-1 (28Yamanaka K. Ishikawa H. Megumi Y. Tokunaga F. Kanie M. Rouault T.A. Morishima I. Minato N. Ishimori K. Iwai K. Nat. Cell Biol. 2003; 5: 336-340Crossref PubMed Scopus (152) Google Scholar), XAP3 (29Cong Y.S. Yao Y.L. Yang W.M. Kuzhandaivelu N. Seto E. J. Biol. Chem. 1997; 272: 16482-16489Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar), or UIP28 (30Martinez-Noel G. Niedenthal R. Tamura T. Harbers K. FEBS Lett. 1999; 454: 257-261Crossref PubMed Scopus (50) Google Scholar), which contains an NZF domain at its N terminus (Fig. 1, A and B). In addition, it contains an intermediate CC domain and a C-terminal RING-IBR region, also known as RBR (31Marin I. Ferrus A. Mol. Biol. Evol. 2002; 19: 2039-2050Crossref PubMed Scopus (83) Google Scholar) or TRIAD domain (32van der Reijden B.A. Erpelinck-Verschueren C.A. Lowenberg B. Jansen J.H. Protein Sci. 1999; 8: 1557-1561Crossref PubMed Scopus (62) Google Scholar), which contains two zinc finger domains and a cystine/histidine-rich motif in between (Fig. 1A). It has been shown that RING-IBR region-containing proteins are involved in E3 ubiquitin ligase activity (31Marin I. Ferrus A. Mol. Biol. Evol. 2002; 19: 2039-2050Crossref PubMed Scopus (83) Google Scholar). RBCK1 is an evolutionarily conserved protein and ubiquitously expressed in all examined tissues in rat (33Tokunaga C. Kuroda S. Tatematsu K. Nakagawa N. Ono Y. Kikkawa U. Biochem. Biophys. Res. Commun. 1998; 244: 353-359Crossref PubMed Scopus (53) Google Scholar). RBCK1 is localized in both the nucleus and the cytoplasm (34Tatematsu K. Yoshimoto N. Koyanagi T. Tokunaga C. Tachibana T. Yoneda Y. Yoshida M. Okajima T. Tanizawa K. Kuroda S. J. Biol. Chem. 2005; 280: 22937-22944Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar). It has been reported that RBCK1 causes ubiquitin-dependent degradation of heme-oxidized IRP2 (iron regulatory protein-2) as an E3 ligase in iron metabolism (28Yamanaka K. Ishikawa H. Megumi Y. Tokunaga F. Kanie M. Rouault T.A. Morishima I. Minato N. Ishimori K. Iwai K. Nat. Cell Biol. 2003; 5: 336-340Crossref PubMed Scopus (152) Google Scholar), facilitates transcriptional coactivation upon HBV infection (29Cong Y.S. Yao Y.L. Yang W.M. Kuzhandaivelu N. Seto E. J. Biol. Chem. 1997; 272: 16482-16489Abstract Full Text Full Text PDF PubMed Scopus (61) Google Scholar), and interacts with various proteins, including UbcM4 E2 ubiquitin ligase (30Martinez-Noel G. Niedenthal R. Tamura T. Harbers K. FEBS Lett. 1999; 454: 257-261Crossref PubMed Scopus (50) Google Scholar), protein kinase C (33Tokunaga C. Kuroda S. Tatematsu K. Nakagawa N. Ono Y. Kikkawa U. Biochem. Biophys. Res. Commun. 1998; 244: 353-359Crossref PubMed Scopus (53) Google Scholar), CREB-binding protein, and PML (34Tatematsu K. Yoshimoto N. Koyanagi T. Tokunaga C. Tachibana T. Yoneda Y. Yoshida M. Okajima T. Tanizawa K. Kuroda S. J. Biol. Chem. 2005; 280: 22937-22944Abstract Full Text Full Text PDF PubMed Scopus (20) Google Scholar). Since RBCK1 contains an NZF domain that is related to the NZF domains of TAB2 and TAB3, we examined whether it associates with TAB2 and TAB3 through homophilic interactions. We transfected 293 cells with expression plasmids for HA-tagged TAB2 or TAB3 and FLAG-tagged RBCK1. Coimmunoprecipitation experiments indicated that RBCK1 interacted with both TAB2 and TAB3 (Fig. 1C). To determine whether RBCK1 is associated with TAB2 and TAB3 under physiological conditions, we raised mouse polyclonal antiserum against recombinant human full-length RBCK1 and TAB2 (Fig. 1D). Anti-TAB2 also recognized TAB3 because of their structural similarity (data not shown). Endogenous coimmunoprecipitation experiments indicated that RBCK1 was associated with TAB2/3 in untransfected 293 cells (Fig. 1E). To determine whether other proteins associated with TAB2 and TAB3 interact with RBCK1, we performed transient transfection and coimmunoprecipitation assays. As shown in Fig. 1F, RBCK1 interacted with TAK1, TRAF6, and RIP but not TRAF2 and TAB1 in these experiments. Domain Mapping of the Interactions between RBCK1 and TAB2/3—It has been reported that the interaction between TAB2/3 and TAK1 is dependent on their respective CC domains (19Takaesu G. Kishida S. Hiyama A. Yamaguchi K. Shibuya H. Irie K. Ninomiya-Tsuji J. Matsumoto K. Mol. Cell. 2000; 5: 649-658Abstract Full Text Full Text PDF PubMed Scopus (491) Google Scholar, 23Ishitani T. Takaesu G. Ninomiya-Tsuji J. Shibuya H. Gaynor R.B. Matsumoto K. EMBO J. 2003; 22: 6277-6288Crossref PubMed Scopus (219) Google Scholar). To determine which domain of RBCK1 facilitates its interaction with TAB2/3, we made a series of RBCK1 deletion mutants (Fig. 2A), including aa 1–220 (carrying NZF), aa 221–500 (carrying CC and RING-IBR), aa 1–270 (carrying NZF and CC), and aa 271–500 (carrying RING-IBR). Coimmunoprecipitation assays indicated that RBCK1 (aa 1–270) interacted with TAB2 as strongly as its full-length did, and RBCK1 (aa 1–220) and RBCK1 (aa 221–500) mutants interacted with TAB2 to a lesser extent compared with the full-length RBCK1 (Fig. 2B). In the same experiment, RBCK1 (aa 271–500) did not interact with TAB2 (Fig. 2B). These observations suggest that the N terminus of RBCK1, which contains the NZF and CC domains, is essential for its interaction with TAB2. Similar results were obtained with TAB3 (data not shown). Similarly, we made a series of TAB2 deletion mutants and determined which domains of TAB2 are required for its interaction with RBCK1 (Fig. 2A). In transient transfection and coimmunoprecipitation experiments, full-length TAB2, TAB2 (aa 55–693), and TAB2 (aa 361–693) interacted with RBCK1 efficiently (Fig. 2C). In the same experiments, TAB2 (aa 1–665) interacted with RBCK1 weakly, whereas TAB2 (aa 1–360) did not interact with RBCK1 (Fig. 2C). These data suggest that TAB2 interacts with RBCK1 through its C-terminal CC- and NZF-containing fragment. Similar results were obtained with TAB3 and its deletion mutants (data not shown). Taken together, our results suggest that the N terminus of RBCK1 and the C terminus of TAB2/3 are required for their interactions. RBCK1 Inhibits TAB2/3-mediated TNF- and IL-1-induced NF-κB Activation—TAB2 and TAB3 are essential for TNF- and IL-1-induced NF-κB activation in a redundant way, and overexpression of TAB2 and TAB3 potently activates NF-κB (19Takaesu G. Kishida S. Hiyama A. Yamaguchi K. Shibuya H. Irie K. Ninomiya-Tsuji J. Matsumoto K. Mol. Cell. 2000; 5: 649-658Abstract Full Text Full Text PDF PubMed Scopus (491) Google Scholar, 23Ishitani T. Takaesu G. Ninomiya-Tsuji J. Shibuya H. Gaynor R.B. Matsumoto K. EMBO J. 2003; 22: 6277-6288Crossref PubMed Scopus (219) Google Scholar, 35Jin G. Klika A. Callahan M. Faga B. Danzig J. Jiang Z. Li X. Stark G.R. Harrington J. Sherf B. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 2028-2033Crossref PubMed Scopus (70) Google Scholar). Since RBCK1 was found to interact with TAB2 and TAB3, we next investigated the effect of RBCK1 on TAB2/3-mediated and TNF- and IL-1-induced NF-κB activation. Reporter gene assays indicated that RBCK1 inhibited TAB2- and TAB3-mediated NF-κB activation in a dose-dependent manner (Fig. 3A). Moreover, RBCK1 inhibited TNF- and IL-1-induced NF-κB activation (Fig. 3B) but did not affect IFN-γ-mediated IRF-1 activation (Fig. 3C). We further determined which domains are responsible for the inhibitory effect of RBCK1 on TAB2/3-mediated NF-κB activation. In reporter gene assays, RBCK1 (aa 221–500) inhibited TAB2- or TAB3-mediated NF-κB activation as potently as the full-length RBCK did, RBCK1 (aa 1–270) and RBCK1 (aa 271–500) inhibited TAB2- or TAB3-mediated NF-κB activation to a lesser degree, and RBCK1 (aa 1–220) had little inhibitory effect (Fig. 3D). Knockdown of RBCK1 Potentiates TNF- and IL-1-induced NF-κB Activation—Since RBCK1 inhibits TNF- and IL-1-induced NF-κB activation in overexpression experiments, we examined whether RBCK1 regulates TNF- and IL-1-induced NF-κB activation under physiological condition. To test this, we made five RNAi plasmids targeting different sites of human RBCK1 mRNA. Transient transfection and Western blot analysis indicated that one of these RNAi plasmids (RBCK1-RNAi-4) could markedly inhibit the expression of transfected and endogenous RBCK1 in 293 cells, whereas the other RNAi plasmids had a little or no effect on RBCK1 expression (Fig. 4, A and B). In reporter gene assays, knockdown of RBCK1 by RBCK1-RNAi-4 plasmid activated NF-κB activation and potentiated TNF- and IL-1-induced NF-κB activation (Fig. 4, C and D). In similar experiments, knockdown of RBCK1 neither activated IRF-1 nor potentiated IFN-γ-induced IRF-1 activation (Fig. 4E). Collectively, these data suggest that RBCK1 is a physiological inhibitor of TNF- and IL-1-induced NF-κB activation pathways. RBCK1 Reduces TAB2/3 Protein Level in a Proteasome-dependent Manner—Since RBCK1 interacts with TAB2/3 and inhibits TNF- and IL-1-induced NF-κB activation, we further investigated the molecular mechanisms responsible for this observation. Previously, it has been shown that RBCK1 is an E3 ubiquitin ligase and involved in proteasome-dependent protein degradation in iron metabolism (28Yamanaka K. Ishikawa H. Megumi Y. Tokunaga F. Kanie M. Rouault T.A. Morishima I. Minato N. Ishimori K. Iwai K. Nat. Cell Biol. 2003; 5: 336-340Crossref PubMed Scopus (152) Google Scholar). Therefore, we determined whether RBCK1 could cause ubiquitination and degradation of TAB2 and TAB3. We transfected 293 cells with expression plasmids for TAB2 and TAK1 together with RBCK1 or its deletion mutants. Western blot analysis indicated that overexpression of RBCK1 caused down-regulation of TAB2 but not TAK1. In addition, RBCK1 (aa 221–500) and RBCK1 (aa 271–500) caused down-regulation of TAB2 but not TAK1, whereas RBCK1 (aa 1–220) and RBCK1 (aa 1–270) had no significant effect on TAB2 protein level (Fig. 5A). Similar results were obtained for TAB3 (data not shown). These results suggest that RBCK1 inhibits TAB2/3-mediated NF-κB activation through degradation of TAB2/3. To determine whether the reduction of TAB2/3 protein levels by RBCK1 is dependent on ubiquitination, we transfected 293 cells with expression plasmids for HA-TAB2 and FLAG-ubiquitin, in combination with empty control plasmid or full-length RBCK1. Coimmunoprecipitation and Western blot analysis indicated that RBCK1 significantly increased ubiquitination of TAB2 (Fig. 5B). Furthermore, the addition of MG132, a specific proteasome inhibitor, rescued TAB2 from RBCK1-mediated degradation (Fig. 5C). Taken together, these observations suggest that RBCK1 negatively regulates TAB2/3-mediated NF-κB activation by causing ubiquitination and proteasome-dependent degradation of TAB2/3. Inflammation is a homeostatic mechanism that limits the effects of infectious agents. TNF and IL-1 are two proinflammatory cytokines, which induce inflammation through activation of the transcription factor NF-κB. In this study, we identified RBCK1 as a negative regulator of TNF- and IL-1-induced NF-κB activation. Various studies have indicated that two homologous and structurally related adapter proteins TAB2 and TAB3 play redundant roles in TNF- and IL-1-mediated NF-κB activation pathways. TAB2 and TAB3 are associated with TAK1, and these protein complexes are recruited to RIP upon TNF stimulation and to TRAF6 upon IL-1 stimulation (4Kanayama A. Seth R.B. Sun L. Ea C.K. Hong M. Shaito A. Chiu Y.H. Deng L. Chen Z.J. Mol. Cell. 2004; 15: 535-548Abstract Full Text Full Text PDF PubMed Scopus (700) Google Scholar, 19Takaesu G. Kishida S. Hiyama A. Yamaguchi K. Shibuya H. Irie K. Ninomiya-Tsuji J. Matsumoto K. Mol. Cell. 2000; 5: 649-658Abstract Full Text Full Text PDF PubMed Scopus (491) Google Scholar, 23Ishitani T. Takaesu G. Ninomiya-Tsuji J. Shibuya H. Gaynor R.B. Matsumoto K. EMBO J. 2003; 22: 6277-6288Crossref PubMed Scopus (219) Google Scholar). Both TAB2 and TAB3 contain CUE, CC, and NZF domains. Among them, NZF domain is highly conserved, and the intact NZF domain is critical for TAB2/3 to bind to Lys63-linked polyubiquitin chains of other adaptor proteins, such as RIP and TRAF6, which are two signaling proteins essential for TNF- and IL-1-induced IKK activation, respectively (4Kanayama A. Seth R.B. Sun L. Ea C.K. Hong M. Shaito A. Chiu Y.H. Deng L. Chen Z.J. Mol. Cell. 2004; 15: 535-548Abstract Full Text Full Text PDF PubMed Scopus (700) Google Scholar). In a search for proteins containing NZF domains conserved with those of TAB2/3, we identified RBCK1, which has been shown to act as an E3 ubiquitin ligase in iron metabolism (28Yamanaka K. Ishikawa H. Megumi Y. Tokunaga F. Kanie M. Rouault T.A. Morishima I. Minato N. Ishimori K. Iwai K. Nat. Cell Biol. 2003; 5: 336-340Crossref PubMed Scopus (152) Google Scholar). Besides an NZF domain, RBCK1 contains a CC motif and a RING-IBR region, indicating that RBCK1 might be multifunctional through association with other proteins. Our coimmunoprecipitation results suggest that RBCK1 interacts with TAB2 and TAB3 both in the mammalian overexpression system and in untransfected cells (Fig. 1, C–E). In addition, RBCK1 interacts with TAK1, TRAF6, and RIP, signaling components that are associated with TAB2/3 (Fig. 1, C–F). These findings suggest that RBCK1 is physically associated with TAB2/3-containing protein complexes. In reporter gene assays, overexpression of RBCK1 inhibits TAB2/3-mediated and TNF- and IL-1-induced NF-κB activation (Fig. 3, A and B), whereas knockdown of RBCK1 by RNAi potentiates TNF- and IL-1-induced NF-κB activation (Fig. 4D). These results suggest that RBCK1 is a physiological suppressor of TNF- and IL-1-induced NF-κB activation pathways. Previously, it has been demonstrated that the RING-IBR domain exerts E3 ubiquitin ligase activity and is involved in proteasome-dependent protein degradation (31Marin I. Ferrus A. Mol. Biol. Evol. 2002; 19: 2039-2050Crossref PubMed Scopus (83) Google Scholar). Our results indicate that the RING-IBR domain is essential for RBCK1 to confer its ubiquitination and proteasome-dependent degradation of TAB2/3 (Fig. 5). Consistently, the RBCK1 mutants that contain the CC and RING-IBR domain also inhibit TAB2/3-mediated NF-κB activation. Furthermore, it has been reported that TAB2/3 are modified by phosphorylation and ubiquitination upon stimulation, which seems to be required for their adaptor functions (23Ishitani T. Takaesu G. Ninomiya-Tsuji J. Shibuya H. Gaynor R.B. Matsumoto K. EMBO J. 2003; 22: 6277-6288Crossref PubMed Scopus (219) Google Scholar). Taken together, these observations support the following model of the role of RBCK1 in TNF- and IL-1-induced signaling. In this model, RBCK1, which is an E3 ubiquitin ligase, is associated with TAB2/3 through their respective CC and NZF domains. This association causes TAB2/3 ubiquitination and degradation and therefore negatively regulates TNF- and IL-1-induced NF-κB activation. Further research could be done to find out the exact mechanism by which RBCK1 exerts the degradation of TAB2/3 in quiescent cells or stimulated cells, if the efficient experimental system is available. Domain mapping experiments suggest that the N-terminal CC- and NZF-containing fragment of RBCK1 (aa 1–270) and the C-terminal CC- and NZF-containing fragment of TAB2 (aa 361–693) are responsible for their interactions (Fig. 2), whereas the C-terminal RING-IBR domain of RBCK1 (aa 271–500) is responsible for catalyzing the ubiquitination of TAB2 (Fig. 5). In our experiments, RBCK1 (aa 221–500) interacts with TAB2/3 weakly but can still efficiently inhibit TAB2/3-mediated NF-κB activation. The simplest explanation for this observation is that the concentration of overexpressed RBCK1 (aa 221–500) is high, and a tight interaction between RBCK1 (aa 221–500) and TAB2/3 is not required for RBCK1 (aa 221–500)-mediated ubiquitination of TAB2/3. This is further supported by the observation that RBCK1 (aa 271–500) could also inhibit TAB2/3-mediated NF-κB activation, although to a lesser degree compared with RBCK1 (aa 221–500) (Fig. 3). In reporter assays, RBCK1 (aa 1–270) also inhibited TAB2/3-mediated NF-κB activation (Fig. 3). Although we do not know the exact mechanism behind this observation, one possible explanation is that RBCK1 (aa 1–270) blocks recruitment of other signaling components in the NF-κB activation pathways to TAB2/3. Host inflammatory responses must be strictly controlled by a variety of negative regulators, because hyperactivation of inflammatory pathways is usually harmful. So far, a number of suppressors of inflammatory signaling have been identified. For example, IRAK-M, a homolog of IRAK1 that is induced by lipopolysaccharide stimulation after 24 h, interacts with MyD88 to negatively regulate its signaling to TRAF6 (36Kobayashi K. Hernandez L.D. Galan J.E. Janeway Jr., C.A. Medzhitov R. Flavell R.A. Cell. 2002; 110: 191-202Abstract Full Text Full Text PDF PubMed Scopus (1150) Google Scholar). A20 inhibits TNF-, IL-1-, TLR-, and RIG-I-induced NF-κB activation pathways by its ubiquitin-editing function (5Wertz I.E. O'Rourke K.M. Zhou H. Eby M. Aravind L. Seshagiri S. Wu P. Wiesmann C. Baker R. Boone D.L. Ma A. Koonin E.V. Dixit V.M. Nature. 2004; 430: 694-699Crossref PubMed Scopus (1470) Google Scholar, 37Gao H. Sun Y. Wu Y. Luan B. Wang Y. Qu B. Pei G. Mol. Cell. 2004; 14: 303-317Abstract Full Text Full Text PDF PubMed Scopus (257) Google Scholar). β-Arrestin inhibits NF-κB activation at both upstream and transcriptional levels (37Gao H. Sun Y. Wu Y. Luan B. Wang Y. Qu B. Pei G. Mol. Cell. 2004; 14: 303-317Abstract Full Text Full Text PDF PubMed Scopus (257) Google Scholar, 38Wang Y. Tang Y. Teng L. Wu Y. Zhao X. Pei G. Nat. Immunol. 2006; 7: 139-147Crossref PubMed Scopus (215) Google Scholar). The inhibitory factors alleviate the inflammatory responses, thereby preventing the host from mounting extraordinary inflammatory responses. The identification of RBCK1 as a novel inhibitor of TNF- and IL-1-induced NF-κB activation pathways provides an additional target and approach for controlling inflammation. We thank members of our laboratory for technical help and stimulating discussion." @default.
• W2128374908 created "2016-06-24" @default.
• W2128374908 creator A5000618507 @default.
• W2128374908 creator A5007695601 @default.
• W2128374908 creator A5027130695 @default.
• W2128374908 creator A5031755873 @default.
• W2128374908 creator A5053204257 @default.
• W2128374908 creator A5077483225 @default.
• W2128374908 creator A5079030954 @default.
• W2128374908 creator A5081820227 @default.
• W2128374908 creator A5083213088 @default.
• W2128374908 creator A5086664284 @default.
• W2128374908 date "2007-06-01" @default.
• W2128374908 modified "2023-09-30" @default.
• W2128374908 title "RBCK1 Negatively Regulates Tumor Necrosis Factor- and Interleukin-1-triggered NF-κB Activation by Targeting TAB2/3 for Degradation" @default.
• W2128374908 cites W1600472471 @default.
• W2128374908 cites W1968336033 @default.
• W2128374908 cites W1969501356 @default.
• W2128374908 cites W1970186446 @default.
• W2128374908 cites W1976382352 @default.
• W2128374908 cites W1977830503 @default.
• W2128374908 cites W1988376074 @default.
• W2128374908 cites W1989166339 @default.
• W2128374908 cites W1990720057 @default.
• W2128374908 cites W1995747121 @default.
• W2128374908 cites W1998160288 @default.
• W2128374908 cites W1998585620 @default.
• W2128374908 cites W1998851985 @default.
• W2128374908 cites W2003996311 @default.
• W2128374908 cites W2005133554 @default.
• W2128374908 cites W2013599007 @default.
• W2128374908 cites W2016194944 @default.
• W2128374908 cites W2018828712 @default.
• W2128374908 cites W2019166246 @default.
• W2128374908 cites W2022247016 @default.
• W2128374908 cites W2030205627 @default.
• W2128374908 cites W2037454778 @default.
• W2128374908 cites W2043981380 @default.
• W2128374908 cites W2050836489 @default.
• W2128374908 cites W2052983672 @default.
• W2128374908 cites W2064558057 @default.
• W2128374908 cites W2078136106 @default.
• W2128374908 cites W2088633139 @default.
• W2128374908 cites W2089938437 @default.
• W2128374908 cites W2095013915 @default.
• W2128374908 cites W2116368522 @default.
• W2128374908 cites W2120009840 @default.
• W2128374908 cites W2120886143 @default.
• W2128374908 cites W2148059499 @default.
• W2128374908 cites W2159795894 @default.
• W2128374908 cites W4248219898 @default.
• W2128374908 doi "https://doi.org/10.1074/jbc.m701913200" @default.
• W2128374908 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17449468" @default.
• W2128374908 hasPublicationYear "2007" @default.
• W2128374908 type Work @default.
• W2128374908 sameAs 2128374908 @default.
• W2128374908 citedByCount "62" @default.
• W2128374908 countsByYear W21283749082012 @default.
• W2128374908 countsByYear W21283749082013 @default.
• W2128374908 countsByYear W21283749082014 @default.
• W2128374908 countsByYear W21283749082015 @default.
• W2128374908 countsByYear W21283749082016 @default.
• W2128374908 countsByYear W21283749082017 @default.
• W2128374908 countsByYear W21283749082018 @default.
• W2128374908 countsByYear W21283749082019 @default.
• W2128374908 countsByYear W21283749082020 @default.
• W2128374908 countsByYear W21283749082021 @default.
• W2128374908 countsByYear W21283749082022 @default.
• W2128374908 countsByYear W21283749082023 @default.
• W2128374908 crossrefType "journal-article" @default.
• W2128374908 hasAuthorship W2128374908A5000618507 @default.
• W2128374908 hasAuthorship W2128374908A5007695601 @default.
• W2128374908 hasAuthorship W2128374908A5027130695 @default.
• W2128374908 hasAuthorship W2128374908A5031755873 @default.
• W2128374908 hasAuthorship W2128374908A5053204257 @default.
• W2128374908 hasAuthorship W2128374908A5077483225 @default.
• W2128374908 hasAuthorship W2128374908A5079030954 @default.
• W2128374908 hasAuthorship W2128374908A5081820227 @default.
• W2128374908 hasAuthorship W2128374908A5083213088 @default.
• W2128374908 hasAuthorship W2128374908A5086664284 @default.
• W2128374908 hasBestOaLocation W21283749081 @default.
• W2128374908 hasConcept C104317684 @default.
• W2128374908 hasConcept C123298856 @default.
• W2128374908 hasConcept C17991360 @default.
• W2128374908 hasConcept C185592680 @default.
• W2128374908 hasConcept C203014093 @default.
• W2128374908 hasConcept C2777730290 @default.
• W2128374908 hasConcept C2778690821 @default.
• W2128374908 hasConcept C2779679103 @default.
• W2128374908 hasConcept C3020084786 @default.
• W2128374908 hasConcept C41008148 @default.
• W2128374908 hasConcept C502942594 @default.
• W2128374908 hasConcept C55493867 @default.
• W2128374908 hasConcept C62478195 @default.
• W2128374908 hasConcept C74172505 @default.
• W2128374908 hasConcept C76155785 @default.
• W2128374908 hasConcept C86339819 @default.
• W2128374908 hasConcept C86803240 @default.

• next